Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that its small-molecule COVID-19 therapy, Xiannuoxin (simnotrelvir, ritonavir), has received regular approval from the Chinese regulatory authorities, converting from its previous conditional approval status. This makes Xiannuoxin the first COVID-19 therapy of its kind to achieve full approval in the country.
The compound drug has demonstrated the ability to rapidly and significantly reduce the virus load by over 96% in clinical trials, with Phase II/III studies indicating good safety and tolerability profiles. It was initially conditionally approved for marketing in China in January of the previous year, providing an important therapeutic option in the fight against COVID-19.- Flcube.com
